Notícias e Atividades da Inhibikase Therapeutics

Inhibikase Therapeutics é uma empresa listada sob o símbolo IKT (US).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Inhibikase Therapeutics

• Mark Iwicki, Chief Executive Officer
• Vincent Aurentz, Director
• Dennis Berman, Director

Criar um alerta
para seguir os movimentos de executivos da Inhibikase Therapeutics.

Inhibikase Therapeutics possui 2.406 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Inhibikase Therapeutics

• Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
• Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
• Press Releases
• Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
• Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
• Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
• Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
• Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
• View more press releases Close

Redes sociais sobre Inhibikase Therapeutics

• Inhibikase Therapeutics na Wikipedia, Google News e Yahoo Finance
• Inhibikase Therapeutics na LinkedIn, X (Twitter) e YouTube